Abstract
Colestipol is an anion exchange resin with bile acid sequestering properties resembling those of cholestyramine, another lipid-lowering binding resin. In daily doses of 15 to 30g colestipol reduces total plasma cholesterol concentrations (primarily low density lipoprotein cholesterol) by about 15 to 30%, but plasma triglyceride concentrations may be unchanged or in some patients increased. Thus, like cholestyramine, colestipol is of benefit in patients with primary hypercholesterolaemia without associated hypertriglyceridaemia (type IIa hyperlipoproteinaemia). Colestipol is odourless and tasteless, and is said by some to be more readily tolerated by patients than cholestyramine, leading to improved compliance, but such data has not been documented in most studies. Side effects of colestipol treatment are primarily gastrointestinal in nature since the drug is essentially unabsorbed. As with cholestyramine, colestipol may bind with other concomitantly administered drugs reducing their absorption or enterohepatic recirculation; dosage intervals of other concurrent medications should be adjusted to minimise the potential for such an interaction.
Citations
May 4, 2005·Cardiovascular Drug Reviews·Karen L Steinmetz, Kristine S Schonder
May 4, 2011·World Journal of Diabetes·Kohzo TakebayashiToshihiko Inukai
Feb 20, 2015·European Heart Journal·Erik S StroesUNKNOWN European Atherosclerosis Society Consensus Panel
Jan 1, 1983·Acta paediatrica Scandinavica·P H GrootJ Fernandes
Jan 1, 1988·Acta paediatrica Scandinavica·P SanjurjoI Cabeza
Jun 12, 2013·Drugs·Venkata M AllaMarc Rendell
Jun 15, 1983·Klinische Wochenschrift·O Leiss, K von Bergmann
Mar 1, 1993·Medicinal Research Reviews·P A McCarthy
Sep 2, 1985·Klinische Wochenschrift·G SchlierfH Schmidt-Gayk
Jun 3, 2016·Expert Opinion on Pharmacotherapy·Jaideep PatelMaciej Banach
Dec 1, 1990·Alimentary Pharmacology & Therapeutics·J C FleishakerA F Hofmann
Jan 1, 1987·Medical Toxicology·L C Knodel, R L Talbert
Feb 1, 1989·Alimentary Pharmacology & Therapeutics·S S RossiA F Hofmann
Nov 1, 1984·Postgraduate Medicine·T R Glatter
Apr 1, 1983·Environmental Health Perspectives·J P Daugherty
Jul 1, 1984·Progress in Cardiovascular Diseases·W V BrownH N Ginsberg